Evolus Inc (EOLS) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million...

Evolus to Hold Investor Day on September 12, 2024

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Launching into this growth market1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical...

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the...

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced...

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company’s geographic expansion strategy Evolus...

Form 8-K - Current report

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities